Certolizumab pegol biosimilar - Pfenex

Drug Profile

Certolizumab pegol biosimilar - Pfenex

Alternative Names: PF 688

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Pfenex
  • Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2017 Preclinical development is ongoing for Rheumatoid arthritis and Crohn's disease in USA
  • 18 Sep 2013 Certolizumab pegol biosimilar - Pfenex is available for licensing as of 18 Sep 2013. http://www.pfenex.com/
  • 31 Dec 2012 Preclinical trials in Crohn's disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top